v3.26.3
Stockholders’ Equity (Deficiency) - Narrative (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended 9 Months Ended
Oct. 01, 2026
Sep. 15, 2026
Aug. 10, 2026
May 31, 2026
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Apr. 02, 2021
Class of Stock [Line Items]                  
Accretion to redemption value         $ 14,239 $ 14,239      
Cash consideration           400 $ 0    
Non-controlling interests         0 0   $ (535)  
Kashiv Specialty Pharmaceuticals, LLC                  
Class of Stock [Line Items]                  
Voting interest acquired (percent)                 98.00%
Kashiv Acquisition | Common Class A                  
Class of Stock [Line Items]                  
Shares issued in connection with the acquisition of Kashiv (in shares)     28.9            
AvKARE, LLC and R&S                  
Class of Stock [Line Items]                  
Payments for repurchase of redeemable noncontrolling interest   $ 19,800              
Accretion to redemption value         $ 14,200 $ 14,200      
Ownership interest (percent)         65.10% 65.10%      
AvKARE, LLC and R&S | Subsequent Event                  
Class of Stock [Line Items]                  
Payments for repurchase of redeemable noncontrolling interest $ 19,800                
Ownership interest (percent) 66.40%                
Kashiv Specialty Pharmaceuticals, LLC | Related Party                  
Class of Stock [Line Items]                  
Ownership percentage by noncontrolling owners (percent)       2.00%          
Cash consideration       $ 400          
Non-controlling interests       $ 600